⇨ Advances for prostate health

More info : https://sites.google.com/view/japanese-method-to-shrink-pros/pioneering-treatment-for-prostate-cancer-with-radioactive-drug-pluvicto The University of Missouri Health Care has launched an innovative treatment for advanced metastatic prostate cancer, using Pluvicto®, a lutetium-177 radiopharmaceutical produced at the university's Research Reactor. This approach, approved by the FDA, shows promise after other treatments. Gregory Biedermann, radiation oncologist, highlights its potential for patients in whom the disease persists. The implementation, part of an innovation approval pathway, is a collaboration between nuclear medicine and radiation oncology. The therapy, administered in six injections, has a short application time and requires no other medications. The university celebrates the success of lutetium-177 and its contribution to beneficial treatments. Following the pilot phase, Pluvicto is expected to be widely available in the future.

Category